Rienzo MB, González CAM, Monjarás GJI, González-Jáuregui LN, Méndez CA, Lemus RRI, Azuara GP, Martínez AY, Barrera GG, Escamilla CM, Rosas RR, Paz CC, Machado VL, Morales BJE

Language: Spanish
References: 18
Page: 16-23
PDF size: 236.43 Kb.

ABSTRACT

Alfa-1 antitrypsin (AAT) deficiency is a genetic disorder characterized by a decreased serum concentration of AAT. AAT inhibits elastase which is the proteolytic enzyme produced by neutrophiles. When a disequilibrium between endogenous protease and antiprotease such as AAT occurs, it can generate pathologies that affect the pulmonary and extra-pulmonary structure and function. It´s importance lies in that it causes 50% of the cases of chronic obstructive pulmonary disease (COPD) in patients younger than 45 years old. These cases are caused by the inability of the antiprotease to destroy the neutrophilic elastase. One of the fundamental aspects in these patient’s treatment is the opportune diagnosis of this disease and the prevention of risk factors that promote the progress of pulmonary function deterioration. This is a review article that analyses not only the most important clinical points of this deficiency, but also offers a synthesis of the most important points in its epidemiology, physiopathology and treatment advances.

REFERENCES

1. Lomas D, Parfrey H. a1-antitrypsin deficiency • 4: Molecular Pathophysiology. Thorax 2004; 59: 529-535.

2. Kubba AK, Young M. The long suffering of Frederic Chopin. Chest 1998; 113:210-216.

3. American Thoracic Society, European Respiratory Society Statement. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003 ;168: 818-900.

4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodríguez-Roisin R, van Weel C, Zielinski J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Global Initiative for Chronic Obstructive Lung Disease. Am J Respir Crit Care Med 2007; 176(6): 527-528.

5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Resp J 2003; 22: 672-688.

6. Devereux G. ABC of chronic obstructive pulmonary disease: Definition, epidemiology and risk factors. British Medical Journal 2006; 332: 1142-1144.

7. Luisetti M, Seersholm N. Epidemiología de la deficiencia de alfa1-antitripsina. Thorax 2004; 59: 164-169.

8. Kohnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis and treatment. Am J Med 2008; 121(1): 3-9.

9. Lee WL, Downey GP. Leukocyte elastase. Physiological functions and role in acute lung injury. Am J Respir Crit Care Med 2001; 1-164(5): 896-904.

10. Shapiro SD. Neutrophil elastase: path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol 2002; 26(3): 290-297.

11. Pepro Tech Inc. Cytokines for the Americas. Serpins, Serpinopathies, and Conformational Diseases. http://www.peprotech .com/content/focusarticles.htm?id=134

12. Lomas D, Carrell R. Alpha-1 antitrypsin deficiency, a model for conformational diseases. N Engl J Med 2002: 346.

13. Kumar. Robbins and Cotran: Pathologic Basis of Disease, 7th ed. Obstructive Pulmonary Diseases.

14. Needham RA. Stockley a1-antitrypsin deficiency • 3: Clinical manifestations and natural history. Thorax 2004; 59: 441-445.

15. Sandhaus RA. a1-Antitrypsin deficiency • 6: New and emerging treatments for a1-antitrypsin deficiency. Thorax 2004; 59: 904-909.

16. Stoller JK, Aboussouan LS. Alpha1-Antitrypsin deficiency • 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708.

17. Lyman HSC, Fairman P. Alpha1-antitrypsin deficiency, 2005: www.emedicine.com/med/topic108

18. Hubbard RC, Crystal RG. Augmentation therapy of alpha 1-antitrypsin deficiency. Eur Respir J Suppl 1998; 9: 44s.